Retinal Gene Therapies Endpoints Get FDA Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
A collaborative effort between Sanofi-Aventis, Oxford BioMedica and the National Neurovision Research Institute is one example of research in genetic treatments for retinal disorders.
You may also be interested in...
How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss
In an interview, Spark President Katherine High explains that multi-luminance mobility test used in clinical development of Spark's gene therapy voretigene sprang from 2011 FDA meeting on need to study functional vision in patients with retinal degenerative diseases. Experience highlights need for new endpoints when targeting previously untreated diseases, she says.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.